Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03884101
Title Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

endometrial carcinoma

Therapies

Carboplatin + Paclitaxel

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.